Overview

Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The hypothesis to be tested is that ticagrelor (Brilinta™) will reduce platelet activation and markers of inflammation in patients with pneumonia.
Phase:
Phase 1
Details
Lead Sponsor:
University of Kentucky
Treatments:
Ticagrelor